Trial Profile

Randomized study to assess the added value of Laromustine in combination with standard remission-induction chemotherapy in patients aged 18-65 years with previously untreated acute myeloid leukemia (AML) or myelodysplasia (MDS) (RAEB with IPSS greater than or equal to 1.5).

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 22 May 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Laromustine (Primary) ; Amsacrine; Cytarabine; Idarubicin
Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Myelodysplastic syndromes; Refractory anaemia
Focus Registrational; Therapeutic Use
Acronyms HOVON-92-AML

15 Mar 2012 This trial has been completed in Belgium and discontinued in Netherlands as reported by European Clinical Trials Database.
15 Mar 2012 Actual initiation date (Sep 2008) added as reported by European Clinical Trials Database.
15 Mar 2012 Planned End Date changed from 30 Sep 2012 to 12 Apr 2013 as reported by European Clinical Trials Database

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com